Triple

T7930813
Position Surface form Disambiguated ID Type / Status
Subject AbbVie E184183 entity
Predicate notableProduct P1448 FINISHED
Object Rinvoq
Rinvoq is a prescription JAK inhibitor medication used to treat various inflammatory and autoimmune conditions such as rheumatoid arthritis and atopic dermatitis.
 E697098 NE FINISHED

How this triple was built (4 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Rinvoq | Statement: [AbbVie, notableProduct, Rinvoq]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07 
Target entity: Rinvoq
Context triple: [AbbVie, notableProduct, Rinvoq]
  • A. Namenda
    Namenda is a prescription medication used to treat moderate to severe Alzheimer's disease by regulating the activity of glutamate in the brain.
  • B. Anpezan
    Anpezan is a regional dialect of the Ladin language spoken in parts of the Dolomite area of northern Italy.
  • C. Darzalex
    Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
  • D. Donepezil
    Donepezil is a cholinesterase inhibitor medication primarily used to treat cognitive symptoms of Alzheimer's disease.
  • E. rivastigmine
    Rivastigmine is a cholinesterase inhibitor medication used to manage symptoms of mild to moderate dementia, particularly in Alzheimer's and Parkinson's disease.
  • F. None of above. chosen
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg Description generation gpt-5.1
Instruction
Generate a one-sentence description of the target entity. 
You are given a context triple in the form (subject, predicate, object), where the object is the target entity. 
# Instructions
Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. 
Avoid repeating the information from the triple, unless really essential.
# Response Format
Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: Rinvoq
Triple: [AbbVie, notableProduct, Rinvoq]
Generated description
Rinvoq is a prescription JAK inhibitor medication used to treat various inflammatory and autoimmune conditions such as rheumatoid arthritis and atopic dermatitis.
NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07 
Target entity: Rinvoq
Target entity description: Rinvoq is a prescription JAK inhibitor medication used to treat various inflammatory and autoimmune conditions such as rheumatoid arthritis and atopic dermatitis.
  • A. Namenda
    Namenda is a prescription medication used to treat moderate to severe Alzheimer's disease by regulating the activity of glutamate in the brain.
  • B. Anpezan
    Anpezan is a regional dialect of the Ladin language spoken in parts of the Dolomite area of northern Italy.
  • C. Darzalex
    Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
  • D. Donepezil
    Donepezil is a cholinesterase inhibitor medication primarily used to treat cognitive symptoms of Alzheimer's disease.
  • E. rivastigmine
    Rivastigmine is a cholinesterase inhibitor medication used to manage symptoms of mild to moderate dementia, particularly in Alzheimer's and Parkinson's disease.
  • F. None of above. chosen

Provenance (5 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69ca8290c21c8190906a5ca6fe2b03c4 completed March 30, 2026, 2:02 p.m.
NER Named-entity recognition batch_69cb3accc388819087065ebe7d5d9591 completed March 31, 2026, 3:09 a.m.
NED1 Entity disambiguation (via context triple) batch_69cb5c01602081908ea1af24785260ff completed March 31, 2026, 5:30 a.m.
NEDg Description generation batch_69cb5f22f89c8190a98208bf096a2427 completed March 31, 2026, 5:44 a.m.
NED2 Entity disambiguation (via description) batch_69cb76d2dff8819085ad9e10baad1537 completed March 31, 2026, 7:25 a.m.
Created at: March 30, 2026, 5:07 p.m.